LINC00839 Regulates Proliferation, Migration, Invasion, Apoptosis and Glycolysis in Neuroblastoma Cells Through MiR-338-3p/GLUT1 Axis

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2021 Jun 30

PMID 34188473

Citations 8

Authors

Lixia Yang

Liangyan Pei

Jilong Yi

Affiliations

Soon will be listed here.

Abstract

Background: Long noncoding RNAs (lncRNAs) are related to the development and treatment of neuroblastoma. The lncRNA LINC00839 is dysregulated in neuroblastoma, while its function and mechanism in neuroblastoma development remain largely unclear.

Methods: The tumor and adjacent noncancerous tissues were collected from 48 neuroblastoma patients. LINC00839, glucose transporter 1 (GLUT1) and microRNA-338-3p (miR-338-3p) abundances were examined via quantitative reverse transcription polymerase chain reaction or Western blot. Cell proliferation, apoptosis, migration, invasion and glycolysis were assessed via Cell Counting Kit-8, colony formation, flow cytometry, wound healing, transwell, glucose uptake and lactate production. The target relationship of miR-338-3p and LINC00839 or GLUT1 was tested via dual-luciferase reporter analysis and RNA immunoprecipitation. The function of LINC00839 on neuroblastoma cell growth in vivo was tested via a xenograft model.

Results: LINC00839 and GLUT1 abundances were increased in neuroblastoma tissues and cell lines. The high expression of LINC00839 and GLUT1 indicated the lower overall survival. LINC00839 interference constrained neuroblastoma cell proliferation, migration, invasion and glycolysis, and facilitated apoptosis. GLUT1 overexpression or miR-338-3p knockdown could mitigate the influence of LINC00839 silence on neuroblastoma cell processes. LINC00839 could regulate GLUT1 expression via miR-338-3p. LINC00839 knockdown reduced neuroblastoma cell growth in xenograft model.

Conclusion: LINC00839 silence repressed neuroblastoma cell proliferation, migration, invasion and glycolysis and promoted apoptosis via regulating miR-338-3p/GLUT1 axis.

Citing Articles

The role of long non-coding RNA LINC00839 in oral squamous cell carcinoma based on bioinformatics and experimental research.

Kalantary-Charvadeh A, Morovat S, Aslani S, Ziamajidi N, Emami Razavi A, Abbasalipourkabir R Sci Rep. 2024; 14(1):31817.

PMID: 39738469 PMC: 11686358. DOI: 10.1038/s41598-024-82922-6.

LINC00839 in Human Disorders: Insights into its Regulatory Roles and Clinical Impact, with a Special Focus on Cancer.

Hu Y, Hu Y, Lu X, Luo H, Chen Z J Cancer. 2024; 15(8):2179-2192.

PMID: 38495499 PMC: 10937278. DOI: 10.7150/jca.93820.

Wu X, Zhang Y, Liang G, Ye H Front Pharmacol. 2023; 14:1199883.

PMID: 37529698 PMC: 10390311. DOI: 10.3389/fphar.2023.1199883.

Glucose metabolism and lncRNAs in breast cancer: Sworn friend.

Xu J, Xu Q, Wang Y, Xu D, Xu W, Zhang H Cancer Med. 2022; 12(4):5137-5149.

PMID: 36426411 PMC: 9972110. DOI: 10.1002/cam4.5265.

LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia.

Xie Y, Lin H, Wei W, Kong Y, Fang Q, Chen E Sci Rep. 2022; 12(1):18757.

PMID: 36335129 PMC: 9637198. DOI: 10.1038/s41598-022-16972-z.

References

Meng X, Fang E, Zhao X, Feng J . Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma. Cancer Med. 2020; 9(11):3800-3815. PMC: 7286466. DOI: 10.1002/cam4.3022. View

He Y, Deng F, Zhao S, Zhong S, Zhao J, Wang D . Analysis of miRNA-mRNA network reveals miR-140-5p as a suppressor of breast cancer glycolysis via targeting GLUT1. Epigenomics. 2019; 11(9):1021-1036. DOI: 10.2217/epi-2019-0072. View

Pastor E, Mousa S . Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019; 138:38-43. DOI: 10.1016/j.critrevonc.2019.03.013. View

Liu X, Zhu Q, Guo Y, Xiao Z, Hu L, Xu Q . LncRNA LINC00689 promotes the growth, metastasis and glycolysis of glioma cells by targeting miR-338-3p/PKM2 axis. Biomed Pharmacother. 2019; 117:109069. DOI: 10.1016/j.biopha.2019.109069. View

Zhang H, Xing M, Guo J, Zhao J, Chen X, Jiang Z . Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway. Cancer Cell Int. 2019; 19:313. PMC: 6880520. DOI: 10.1186/s12935-019-0968-x. View

Chen X, Yu J, Tian H, Shan Z, Liu W, Pan Z . Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR-378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter-1 (GLUT1) and glycolysis. J Cell Physiol. 2019; 234(11):19130-19140. DOI: 10.1002/jcp.28692. View

Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View

Aygun N . Biological and Genetic Features of Neuroblastoma and Their Clinical Importance. Curr Pediatr Rev. 2018; 14(2):73-90. DOI: 10.2174/1573396314666180129101627. View

Louis C, Shohet J . Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2014; 66:49-63. PMC: 4418018. DOI: 10.1146/annurev-med-011514-023121. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

12.

Aminzadeh S, Vidali S, Sperl W, Kofler B, Feichtinger R . Energy metabolism in neuroblastoma and Wilms tumor. Transl Pediatr. 2016; 4(1):20-32. PMC: 4729069. DOI: 10.3978/j.issn.2224-4336.2015.01.04. View

13.

Galardi A, Colletti M, Businaro P, Quintarelli C, Locatelli F, Di Giannatale A . MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential. Curr Med Chem. 2017; 25(5):584-600. DOI: 10.2174/0929867324666171003120335. View

14.

Zhang N, Liu F, Ma T, Zhang Z . LncRNA SNHG1 contributes to tumorigenesis and mechanism by targeting miR-338-3p to regulate PLK4 in human neuroblastoma. Eur Rev Med Pharmacol Sci. 2019; 23(20):8971-8983. DOI: 10.26355/eurrev_201910_19296. View

15.

Peng Y, Xing S, Tang H, Wang C, Yi F, Liu G . Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro. Gene. 2018; 689:11-17. DOI: 10.1016/j.gene.2018.12.010. View

16.

Ramani P, Headford A, May M . GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 2013; 462(2):203-9. DOI: 10.1007/s00428-012-1370-4. View

17.

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

18.

Chen J, Cao L, Li Z, Li Y . SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. Hum Cell. 2019; 32(2):193-201. DOI: 10.1007/s13577-019-00237-5. View

19.

Chen X, Pan M, Han L, Lu H, Hao X, Dong Q . miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013; 587(22):3729-37. DOI: 10.1016/j.febslet.2013.09.044. View

20.

Ganapathy-Kanniappan S, Geschwind J . Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013; 12:152. PMC: 4223729. DOI: 10.1186/1476-4598-12-152. View